STI Stock Trade Intelligence
NYR

NYRADA INC.

Health Care · ASX:NYR
$0.5000
▼ -0.99%
Market cap
$130M
Turnover
$60,658
Last price
$0.5000
Day change
-0.99%
Announcements
17
Range, past year
Open 0.655 · Low 0.095 · Now 0.500 · High 1.435
Open NYR in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

NYR momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
31/100
Wyckoff phase
Accumulation19d
Trend stage
Neutral
1 Day
-1.0%
1 Week
+6.4%
1 Month
+6.4%
1 Year
-31.0%
RSI
51
Avg daily range
6.5%

NYRADA INC. scores 31 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 19 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently outperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -48.8%
  • High volatility (ATR 6.5%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
NYR appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

NYR announcements

Recent price-sensitive releases.
  • 2026-10-19 Quarterly Activities Report and Appendix 4C Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-13 Nyrada Receives Positive FDA Feedback Progress Report
  • 2026-10-12 Attaching Options Prospectus Disclosure Document
  • 2026-09-21 Nyrada Successfully Raises AU$12.0 Million Via Placement Placement | Trading Halt Lifted | Security Purchase Plan
  • 2026-09-21 Cap Raise Deck-Building the Future of TRPC-based Therapies Company Presentation | Placement | Security Purchase Plan
  • 2026-09-17 Trading Halt Trading Halt
  • 2026-08-21 Xolatryp Demonstrates Cardioprotection in Preclinical Study Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.